ABSTRACT
Objective@#To observe the clinical efficacy of different dialysis frequency and methods in the treatment of chronic renal failure uremia patients, and to provide a reliable reference for clinical practice.@*Methods@#From February 2016 to February 2017, 140 chronic renal failure uremic patients who admitted to the Department of Nephrology at Taizhou Central Hospital were selected and divided into the observation group and the control group by complete random distribution method, with 70 cases in each group.The patients in the control group received 3 times of regular hemodialysis treatment per week, while the observation group received 3 times of regular hemodialysis combined with 1 time of hemodiafiltration treatment per week.The clinical treatment effects and complications of the two groups were compared.@*Results@#Compared with blood uric acid(BUA)[(532.09±71.05)mmol/L], serum creatinine(Scr)[(734.34±63.08)μmol/L], blood urea(BUN)[(23.84±2.58)mmol/L], serum phosphorus[(1.98±0.37)mmol/L], parathyroid hormone(PTH)[(464.37±113.92)ng/L], β2 microglobulin(β2-MG)[(13.48±6.38)mg/L]in the control group, BUA[(495.89±58.23)mmol/L], Scr[(684.34±77.32)μmol/L], BUN[(20.62±1.77)mmol/L], serum phosphorus[(1.74±0.44)mmol/L], PTH[(352.14±123.25)ng/L], β2-MG[(9.58±5.45)mg/L] were significantly lower in the observation group, the differences were statistically significant (t=3.29, 4.19, 8.61, 3.49, 5.59, 3.88, all P<0.01). Compared with the incidence rate of pruritus in the control group(61.43%), the incidence rate of pruritus in the observation group(34.29%) was significantly lower (χ2=9.72, P<0.01), the incidence of other complications had no statistically significant differences(χ2=1.14, 1.58, 3.08, all P>0.05).@*Conclusion@#Hemodialysis 3 times combined with 1 time of hemodiafiltration per week has significant advantage in the treatment of chronic renal failure uremia patients, which can effectively remove urine toxin molecules and reduce the incidence of complications, and it is worthy of clinical application.
ABSTRACT
Objective To observe the clinical efficacy of different dialysis frequency and methods in the treatment of chronic renal failure uremia patients ,and to provide a reliable reference for clinical practice.Methods From February 2016 to February 2017,140 chronic renal failure uremic patients who admitted to the Department of Nephrology at Taizhou Central Hospital were selected and divided into the observation group and the control group by complete random distribution method ,with 70 cases in each group.The patients in the control group received 3 times of regular hemodialysis treatment per week , while the observation group received 3 times of regular hemodialysis combined with 1 time of hemodiafiltration treatment per week.The clinical treatment effects and complications of the two groups were compared.Results Compared with blood uric acid ( BUA) [(532.09 ±71.05) mmol／L],serum creatinine(Scr) [(734.34 ±63.08) μmol／L],blood urea ( BUN) [(23.84 ±2.58) mmol／L],serum phosphorus [(1.98 ±0.37)mmol／L],parathyroid hormone ( PTH) [(464.37 ±113.92) ng／L],β2 microglobulin ( β2 -MG) [(13.48 ±6.38)mg／L]in the control group,BUA[(495.89 ±58.23) mmol／L],Scr[(684.34 ±77.32)μmol／L], BUN[(20.62 ±1.77) mmol／L],serum phosphorus [(1.74 ±0.44) mmol／L],PTH[(352.14 ±123.25) ng／L], β2 -MG[(9.58 ±5.45) mg／L] were significantly lower in the observation group ,the differences were statistically significant (t＝3.29,4.19,8.61,3.49,5.59,3.88,all P＜0.01).Compared with the incidence rate of pruritus in the control group(61.43%),the incidence rate of pruritus in the observation group (34.29%) was significantly lower (χ2 ＝9.72,P＜0.01),the incidence of other complications had no statistically significant differences ( χ2 ＝1.14, 1.58,3.08,all P＞0.05).Conclusion Hemodialysis 3 times combined with 1 time of hemodiafiltration per week has significant advantage in the treatment of chronic renal failure uremia patients ,which can effectively remove urine toxin molecules and reduce the incidence of complications ,and it is worthy of clinical application.
